Literature DB >> 9715825

Treatment guidelines in heart failure.

M A Konstam1, W J Remme.   

Abstract

The risk of heart failure increases with age. Prognosis is poor, with 82% of patients dying within 6 years of diagnosis. As the population ages, heart failure is becoming an increasing problem. Heart failure is a complex disease that may be managed in a variety of ways depending on its severity and cause. A wide range of pharmacological and nonpharmacological therapeutic measures are available to relieve symptoms and prolong life. These have changed considerably in the last decade. Cardiology experts in the United States and Europe have developed guidelines for the diagnosis and management of heart failure. These are intended to help physicians to keep up with therapeutic developments and to encourage more appropriate and cost-effective management of patients with heart failure. The European guidelines were updated more recently than their US counterparts and consequently contain certain new developments, such as the inclusion of the latest data on beta-blockers, including carvedilol, that have shown morbidity and mortality rate benefits in patients with mild-to-moderate heart failure. As the management of heart failure is changing rapidly, regular schemes for updating of guidelines are being considered.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9715825     DOI: 10.1016/s0033-0620(98)80033-9

Source DB:  PubMed          Journal:  Prog Cardiovasc Dis        ISSN: 0033-0620            Impact factor:   8.194


  2 in total

Review 1.  Losartan: a review of its use, with special focus on elderly patients.

Authors:  K L Simpson; K J McClellan
Journal:  Drugs Aging       Date:  2000-03       Impact factor: 3.923

2.  Linkage of beta1-adrenergic stimulation to apoptotic heart cell death through protein kinase A-independent activation of Ca2+/calmodulin kinase II.

Authors:  Wei-Zhong Zhu; Shi-Qiang Wang; Khalid Chakir; Dongmei Yang; Tong Zhang; Joan Heller Brown; Eric Devic; Brian K Kobilka; Heping Cheng; Rui-Ping Xiao
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.